BMJ noted that pharmaceutical companies increasingly include DORIS remission as a key secondary endpoint in lupus clinical trials.
Published
Signal category
Research & Knowledge
Quote
“and its influence extends into drug development. Pharmaceutical companies increasingly include DORIS remission as a key secondary endpoint in lupus clinical trials”
— BMJ team
Company
BMJ
Global healthcare knowledge provider & publisher of The BMJ, one of the world's top five general medical journals.
- Industry
- Technology, Information and Media
- Location
- London, GB
- Company size
- 1,314 employees
BMJ Group is a global healthcare knowledge provider. Our vision of a healthier world drives what we do; by sharing knowledge and expertise we help to improve patient outcomes through better evidence, better decisions and better systems. As an employer, and as a leading voice in global medicine and health, we strongly believe in anti-racism and equity because more equal societies are healthier societies. We prioritise inclusion and diversity within our company and as part of the communities we serve.
Founded 1840